Study of the immunogenicity of outer membrane protein A (ompA) gene from Acinetobacter baumannii as DNA vaccine candidate in vivo

Document Type : Original Article


1 Department of Genetics, Marvdasht branch, Islamic Azad University, Marvdasht, Iran

2 Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Departments of Biotechnology, Ahvaz Branch, Islamic Azad University, Ahvaz, Iran

4 Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Iran

5 Biotechnology Research Center, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran

6 Department of Microbiology, Jahrom Branch, Islamic Azad University, Jahrom, Iran


Objective(s): Acinetobacter baumannii is one the most dangerous opportunistic pathogens in hospitalized infections. This bacterium is resistant to 90% of commercial antibiotics. Therefore, developing new strategies to cure A. baumannii-infections is urgent. The DNA vaccines new approach in which the immunogen can be directly expressed inside the target cells through cloning of immunogen into an expression vector. The outer membrane protein A(OmpA) is one the critical factors in pathogenicity of A. baumannii which has been repeatedly described as a powerful immunogen to trigger the immune responses. As the pure form of the OmpA is insoluble, vaccine delivery is very hard.
Materials and Methods: We previously cloned the ompA gene from A. baumannii into the eukaryotic expression vector pBudCE4.1 and observed that the OmpA protein has been considerably expressed in eukaryotic cell model. In current study, the immunogenic potential of pBudCE4.1-ompA has been evaluated in mice model of experimental. The serum levels of IgM, IgG, IL-2, IL-4, IL-12 and INF-γ were measured by enzyme-linked immunosorbent assay (ELISA) after immunization with ompA-vaccine. The protective efficiency of the designed-DNA vaccine was evaluated following intranasal administration of mice with toxic dose of A. baumannii.
Results: Obtained data showed the elevated levels of IgM, IgG, IL-2, IL-4, IL-12 and INF-γ in serum following the vaccine administration and mice who immunized with recombinant vector were survived more than control group.
Conclusion: These findings indicate ompA-DNA vaccine is potent to trigger humoral and cellular immunity responses although further experiments are needed.


Main Subjects

1. Chen T-L, Lee Y-T, Kuo S-C, Yang S-P, Fung C-P, Lee S-D. Rapid identification of Acinetobacter baumannii, Acinetobacter nosocomialis and Acinetobacter pittii with a multiplex PCR assay. J Med Microbiol. 2014; 63:1154-1159.
2. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006; 42:692-699.
3. Singh R, Garg N, Shukla G, Capalash N, Sharma P. Immunoprotective efficacy of Acinetobacter baumannii outer membrane protein, FilF, predicted in silico as a potential vaccine candidate. Front Microbiol. 2016; 7: 1-9.
4. Ansari H, Doosti A, Kargar M, Bizhanzadeh M, Jafarinya M. Cloning and sequencing of the ompA and smpA virulence genes of acentobacter baumannii isolated in clinical samples. Armaghane danesh 2017; 21:1207-1217.
5. Japoni-Nejad A, Sofian M, van Belkum A, Ghaznavi-Rad E. Nosocomial outbreak of extensively and pan drug-resistant Acinetobacter baumannii in tertiary hospital in central part of Iran. Jundishapur J Microbiol. 2013; 6:1-5.
6. Birgani MT, Bijanzadeh M, Ansari H. Antibiotic Characterization of Acinetobacter baumannii isolated from clinical samples and production of recombinant OmpA from resistant strains. Jundishapur J Microbiol 2018; 11: e78773.
7. Talbot GH, Bradley J, Edwards Jr JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial Availability task force of the infectious diseases society of america. Clin Infect Dis 2006; 42:657-668.
8. Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis.  2008; 46:1254-1263.
9. McConnell MJ, Domínguez-Herrera J, Smani Y, López-Rojas R, Docobo-Pérez F, Pachón J. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun. 2011; 79:518-526.
10. Ni Z, Chen Y, Ong E, He Y. Antibiotic resistance determinant-focused Acinetobacter baumannii vaccine designed using reverse vaccinology. Int J Mol Sci 2017; 18:458-480.
11. Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines 2016; 15:313-329.
12. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol 2012; 162:171-182.
13. Do Carmo FLR, Carvalho RD, Jan G, Azevedo V. Therapeutic DNA vaccines: The final step for success. J Bacteriol Parasitol 2017; 8:1-2.
14. Moriel DG, Beatson SA, Wurpel DJ, Lipman J, Nimmo GR, Paterson DL, et al. Identification of novel vaccine candidates against multidrug-resistant Acinetobacter baumannii. PLoS One 2013; 8:1-9.
15. Sato Y, Unno Y, Kawakami S, Ubagai T, Ono Y. Virulence characteristics of Acinetobacter baumannii clinical isolates vary with the expression levels of omps. J Med Microbiol. 2017; 66:203-212.
16. Smani Y, Fàbrega A, Roca I, Sánchez-Encinales V, Vila J, Pachón J. Role of OmpA in the multidrug resistance phenotype of Acinetobacter baumannii. Antimicrob Agents Chemother 2014; 58:1806-1808.
17. Smith SG, Mahon V, Lambert MA, Fagan RP. A molecular Swiss army knife: OmpA structure, function and expression. FEMS Microbiol Lett 2007; 273:1-11.
18. Ansari H,  Doosti A, Kargar M, Bijanzadeh M and Jaafarinia M. Cloning of ompA gene from Acinetobacter baumannii into the eukaryotic expression vector pBudCE4.1 as DNA vaccine. Indian J Microbiol. 2017; 58; 174–181
19. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev.  2008; 21:538-582.
20. Ansari H, Doosti A, Kargar M, Bijanzadeh M, Jaafarinia M. Cloning of ompA gene from Acinetobacter baumannii into the eukaryotic expression vector pBudCE4. 1 as DNA vaccine. Indian J Microbiol 2017; 58:174–181
21. Ansari H, Doosti A, Kargar M, Bijanzadeh M, Jafarinya M. Antimicrobial resistant determination and prokaryotic expression of smpA gene of Acinetobacter baumannii isolated from admitted patients. Jundishapur J Microbiol 2017; 10: 1-10.
22. Kempf M, Rolain J-M. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012; 39:105-114.
23. Moradi J, Hashemi FB, Bahador A. Antibiotic resistance of Acinetobacter baumannii in Iran: a systemic review of the published literature. Osong Public Health Res Perspect.  2015; 6:79-86.
24. Pourhajibagher M, Hashemi FB, Pourakbari B, Aziemzadeh M, Bahador A. Antimicrobial resistance of Acinetobacter baumannii to imipenem in Iran: a systematic review and meta-analysis. Open Microbiol J. 2016; 10:32-42.
25. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011; 53:296-302.
26. Pavlakis G, Kulkarni V, Valentin A, Rosati M, Sardesai N, Mothe B, et al. DNA vaccines expressing conserved elements provide potent and broad immune responses. Retrovirology 2012; 9:O67.
27. García-Patiño MG, García-Contreras R, Licona-Limón P. The immune Response against Acinetobacter baumannii, an emerging pathogen in nosocomial infections. Front Immunol. 2017; 8: 1-10.
28. Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol. 2010; 10:778-786.
29. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012; 12:180-190.
30. Prussin C, Yin Y, Upadhyaya B. Th 2 heterogeneity: Does function follow form? J Allergy Clin Immunol.  2010; 126:1094-1098.
31. Tadmori W, Lee H, Clark S, Choi Y. Human B cell proliferation in response to IL-4 is associated with enhanced production of B cell-derived growth factors. J Immunol. 1989; 142:826-832.
32. Mandler R, Finkelman FD, Levine AD, Snapper CM. IL-4 induction of IgE class switching by lipopolysaccharide-activated murine B cells occurs predominantly through sequential switching. J Immunol. 1993; 150:407-418.
33. Hsieh C-S, Macatonia SE, Tripp CS, Wolf SF, O’GARRA A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by listeria-induced macrophages. J Immunol. 2008; 181:4437-4439.
34. Zhang C, Zhang J, Niu J, Zhou Z, Zhang J, Tian Z. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum immunol 2008; 69:490-500.
35. Eshleman EM, Lenz LL. Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity. Front Immunol.  2014; 5: 1-11.
36. Chesler DA, Reiss CS. The role of IFN-γ in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev 2002; 13:441-454.
37. Mah AY, Cooper MA. Metabolic Regulation of Natural Killer Cell IFN-γ Production. CRIT REV IMMUNOL 2016; 36: 131-147.
38. Vardjan N, Gabrijel M, Potokar M, Švajger U, Kreft M, Jeras M, et al. IFN-γ-induced increase in the mobility of MHC class II compartments in astrocytes depends on intermediate filaments. J Neuroinflammation. 2012; 9:144-157
39. Lin L, Tan B, Pantapalangkoor P, Ho T, Hujer AM, Taracila MA, et al. Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine 2013; 31:313-318.
40. Alzubaidi AN, Alkozai ZM. Immunogenic properties of outer membrane protein of Acinetobacter baumannii that loaded on chitosan nanoparticles. Am J BioMed 2015; 3:59-74.
41. Yan Z, Yang J, Hu R, Hu X, Chen K. Acinetobacter baumannii infection and IL-17 mediated immunity. Mediators Inflamm. 2016; 2016:1-5
42. Zhang X, Yang T, Cao J, Sun J, Dai W, Zhang L. Mucosal immunization with purified OmpA elicited protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii. Microb Pathog 2016; 96:20-25.
43. Ahmad TA, Tawfik DM, Sheweita SA, Haroun M, El-Sayed LH. Development of immunization trials against Acinetobacter baumannii Trials Vaccinol. 2016; 5:53-60.
44. Al-Warid R, Al-Thahab A. Cellular immune response to outer membrane proteins isolated. IJONAS 2014; 2:91-96.
45. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release. 2004; 100:5-28.
46. Mirgani MT, Isacchi B, Sadeghizadeh M, Marra F, Bilia AR, Mowla SJ, et al. Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells. Int J Nanomedicine. 2014; 9:403-417.
47. Tahmasebi Birgani M, Erfani-Moghadam V, Babaei E, Najafi F, Zamani M, Shariati M, et al. Dendrosomal nano-curcumin; The novel formulation to improve the anticancer properties of curcumin. PBS  2015; 5:143-158.